- Clinical-stage biopharma Zentalis Pharmaceuticals ( NASDAQ: ZNTL ) on Tuesday said it had appointed its co-founder Kevin Bunker as chief scientific officer.
- "In this new role, (Bunker) will focus on leading Research and Development (R&D) in San Diego, advancing the preclinical pipeline and optimizing the Company’s Integrated Discovery Engine," the company said in a statement .
- Bunker had previously been chief operating officer at the company.
- ZNTL stock earlier closed +3.8% at $21.
For further details see:
Zentalis Pharmaceuticals promotes co-founder Kevin Bunker to chief scientific officer